Takami Hiroshi, Ito Yasuhiro, Okamoto Takahiro, Onoda Naoyoshi, Noguchi Hitoshi, Yoshida Akira
Department of Surgery, Ito Hospital, Tokyo, Japan.
World J Surg. 2014 Aug;38(8):2002-10. doi: 10.1007/s00268-014-2498-y.
In 2010, the Japanese Society of Thyroid Surgeons (JSTS) and Japanese Association of Endocrine Surgeons (JAES) established new guidelines entitled "Treatment of Thyroid Tumors." Since then, several new studies, including those that address the treatment of differentiated thyroid carcinoma (DTC) have been published, and the DTC treatment policy not only of Japanese physicians but those in Western countries has continued to evolve.
We selected six clinical questions regarding the treatment of DTC and revisited them based on newly published data from Western countries and Japan.
More data have accumulated about treatment of low-risk papillary microcarcinoma. It has become clear that conservative treatment (observation) of low-risk papillary microcarcinoma in elderly patients is an acceptable alternative to immediate surgery. Total thyroidectomy versus hemithyroidectomy for low-risk papillary thyroid carcinoma (PTC) has become an important issue, and some publications after 2010 indicated that hemithyroidectomy is adequate for these low-risk patients. Unfortunately, no published manuscripts on prophylactic central node dissection offered good evidence regarding its indications or included a large number of patients. Also, it was not evident that prophylactic lateral node dissection improves cause-specific survival, although it might reduce lymph node recurrence especially in PTC patients with large tumors, distant metastases, or clinical central node metastases. Although completion total thyroidectomy was not recommended for minimally invasive follicular thyroid carcinoma in our guidelines, it may be better to perform it in elderly patients and those with a large tumor or extensive vascular invasion. Radioactive iodine (RAI) ablation after total thyroidectomy is still performed almost routinely in many Western institutions, although recent studies showed that ablation is not beneficial in low-risk patients. In Japan, because of legal restrictions, most patients did not undergo RAI ablation, and their prognoses are excellent.
Recently, policy for treating DTCs has changed not only in Western countries but also in Japan, resulting in a gradual move toward consensus between Western practice and ours. We will continue to present the best treatments for patients with thyroid carcinoma each time we revise our guidelines.
2010年,日本甲状腺外科医师协会(JSTS)和日本内分泌外科医师协会(JAES)制定了新的指南,题为《甲状腺肿瘤的治疗》。从那时起,包括一些关于分化型甲状腺癌(DTC)治疗的新研究已经发表,并且不仅日本医生,西方国家医生的DTC治疗策略也在不断演变。
我们选择了六个关于DTC治疗的临床问题,并根据西方国家和日本新发表的数据对其进行重新审视。
关于低危乳头状微小癌的治疗已经积累了更多数据。老年患者低危乳头状微小癌的保守治疗(观察)已成为立即手术的可接受替代方案,这一点已变得清晰。低危乳头状甲状腺癌(PTC)行全甲状腺切除术与半甲状腺切除术已成为一个重要问题,2010年后的一些出版物表明半甲状腺切除术对这些低危患者是足够的。遗憾的是,关于预防性中央区淋巴结清扫的已发表手稿均未提供关于其适应证的充分证据,也未纳入大量患者。此外,预防性侧方淋巴结清扫虽可能降低淋巴结复发,尤其是在肿瘤较大、有远处转移或临床中央区淋巴结转移的PTC患者中,但并不明显改善病因特异性生存率。尽管我们的指南不建议对微创滤泡状甲状腺癌行甲状腺全切术,但对于老年患者以及肿瘤较大或有广泛血管侵犯的患者,行甲状腺全切术可能更好。甲状腺全切术后放射性碘(RAI)消融在许多西方机构仍几乎常规进行,尽管最近的研究表明消融对低危患者并无益处。在日本,由于法律限制,大多数患者未接受RAI消融,但其预后良好。
最近,不仅西方国家,日本的DTC治疗策略也发生了变化,导致西方实践与我们的实践逐渐趋于一致。每次修订指南时,我们都将继续为甲状腺癌患者提供最佳治疗方案。